Dutch Bros Inc. to Participate in Four Spring Investor Conferences

Dutch Bros Inc. to Participate in Four Spring Investor Conferences

GRANTS PASS, Ore.–(BUSINESS WIRE)–
Dutch Bros Inc. (NYSE: BROS; “Dutch Bros” or “the “Company”) one of the fastest-growing brands in the food service and restaurant industry in the United States by location count, today announced that the Company will participate in four spring investor conferences:

  • The Company will host a fireside chat at Baird’s 2022 Global Consumer, Technology & Services Conference on Tuesday, June 7, 2022 beginning at 1:55 p.m. Eastern Time and will be meeting with institutional investors throughout the day.
  • The Company will host a fireside chat at Piper Sandler’s Year of the Restaurant Industry Summit on Wednesday, June 8, 2022 beginning at 9:00 a.m. Eastern Time and will be meeting with institutional investors throughout the day. The fireside chat will not be webcasted.
  • The Company will host a fireside chat at William Blair’s 42nd Annual growth Stock Conference on Thursday, June 9, 2022 beginning at 1:20 p.m. Eastern Time and will be meeting with institutional investors throughout the day.
  • The Company will host a virtual fireside chat as part of the Jefferies Consumer Conference which will be available beginning on Monday, June 20, 2022. The Company will also be meeting in person with institutional investors on Tuesday, June 21, 2022 and Wednesday, June 22, 2022.

The fireside chats will be webcast live from the Investor Relations website at https://investors.dutchbros.com/ under “Events & Presentations”.

About Dutch Bros Inc.

Dutch Bros Inc. (NYSE: BROS) is a high growth operator and franchisor of drive-thru shops that focus on serving high QUALITY, hand-crafted beverages with unparalleled SPEED and superior SERVICE. Founded in 1992 by brothers Dane and Travis Boersma, Dutch Bros began with a double-head espresso machine and a pushcart in Grants Pass, Oregon. While espresso-based beverages are still at the core of what we do, Dutch Bros now offers a wide variety of unique, customizable cold and hot beverages that delight a broad array of customers. We believe Dutch Bros is more than just the products we serve—we are dedicated to making a massive difference in the lives of our employees, customers and communities. This combination of hand-crafted and high-quality beverages, our unique drive-thru experience and our community-driven, people-first culture has allowed us to successfully open new shops and continue to share the “Dutch Luv” at 572 locations across 12 states as of March 31, 2022.

To learn more about Dutch Bros, visit www.dutchbros.com, follow Dutch Bros Coffee on Instagram, Facebook, Twitter, and TikTok, and download the Dutch Bros app to earn points and score rewards!

For Investor Relations Inquiries:

Raphael Gross of ICR

203.682.8253

[email protected]

For Media Relations Inquiries:

Jessica Liddell of ICR

203.682.8208

[email protected]

KEYWORDS: Oregon United States North America

INDUSTRY KEYWORDS: Retail Restaurant/Bar Food/Beverage

MEDIA:

MP Materials to Participate in Upcoming Conferences

MP Materials to Participate in Upcoming Conferences

LAS VEGAS–(BUSINESS WIRE)–
MP Materials Corp. (NYSE: MP) today announced that Ryan Corbett, Chief Financial Officer, will participate in the following conferences:

The BMO Rare Earth Supply Chain Conference on Tuesday, June 7, 2022, at 11:00 a.m. Eastern Time.

The Deutsche Bank 13th Annual Global Materials Conference on Wednesday, June 8, 2022, at 9:45 a.m. Eastern Time.

A live webcast and replay of both events will be available at https://investors.mpmaterials.com/.

About MP Materials

MP Materials Corp. (NYSE: MP) is the largest producer of rare earth materials in the Western Hemisphere. The Company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility (“Mountain Pass”), America’s only active and scaled rare earth mining and processing site. MP Materials produced approximately 15% of the rare earth content consumed in the global market in 2021. Separated rare earth elements are critical inputs for the magnets that enable the mobility of electric vehicles, drones, defense systems, wind turbines, robotics and many other high-growth, advanced technologies. MP Materials’ integrated operations at Mountain Pass combine low production costs with high environmental standards, thereby restoring American leadership to a critical industry with a strong commitment to sustainability. More information is available at https://mpmaterials.com/.

Join the MP Materials community on Twitter, Instagram and LinkedIn.

Investors:

[email protected]

Media:

Matt Sloustcher

[email protected]

KEYWORDS: Nevada United States North America

INDUSTRY KEYWORDS: Mining/Minerals Natural Resources

MEDIA:

Logo
Logo

F5 to Participate in BofA Securities 2022 Global Technology Conference

F5 to Participate in BofA Securities 2022 Global Technology Conference

SEATTLE–(BUSINESS WIRE)–
F5, Inc. (NASDAQ: FFIV) today announced that it will participate in the BofA Securities 2022 Global Technology Conference.

F5’s presentation will be webcast live beginning at 2:50 p.m. ET on Thursday, June 9, 2022. Interested attendees can access the live webcast via the Investor Relations section of f5.com or via this link. An archived version of the webcast will be available on F5’s Investor Relations page.

About F5

F5 (NASDAQ: FFIV) is a multi-cloud application security and delivery company that enables our customers—which include the world’s largest enterprises, financial institutions, service providers, and governments—to bring extraordinary digital experiences to life. For more information, go to f5.com. You can also follow @F5 on Twitter or visit us on LinkedIn and Facebook for more information about F5, its partners, and technologies.

F5 is a trademark, service mark, or tradename of F5, Inc., in the U.S. and other countries. All other product and company names herein may be trademarks of their respective owners.

SOURCE: F5, Inc.

Suzanne DuLong

(206) 272-7049

[email protected]

KEYWORDS: Washington United States North America

INDUSTRY KEYWORDS: Internet Security Data Management Technology Software

MEDIA:

Logo
Logo

Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)

Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)

Repare will receive a $125million upfrontpayment and is eligible to receive up to anadditional $1.2 billion in potential development, regulatory, commercial and sales milestones, plus royalties on global net product sales

Repare to host conference call today at 5:00 p.m. EDT

CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE)–
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib (also known as RP-3500), a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of tumors with specific synthetic-lethal genomic alterations including those in the ATM gene (Ataxia-Telangiectasia mutated kinase). Under the collaboration, Roche will assume development of camonsertib with the potential to expand development into additional tumors and multiple combination studies.

“Camonsertib has the potential to help cancer patients across numerous solid tumors as a monotherapy and possibly in combination with other agents,” said Kim Seth, Ph.D., EVP and Head of Business & Corporate Development at Repare. “Given the encouraging data Repare has generated for camonsertib as a potentially best-in-class ATR inhibitor with a promising tolerability profile and patient selection insights in areas of high unmet medical need, and Roche’s leading global footprint and unique expertise in precision oncology, we are confident that Roche is the ideal partner for us to drive the broad global development and commercialization of camonsertib.”

“Roche is excited about the emerging DNA damage response field, which represents a promising new approach to precision oncology,” said James Sabry, M.D., Ph.D., Global Head of Pharma Partnering, Roche. “We are looking forward to partnering with Repare Therapeutics to further develop camonsertib as a new potential treatment option for patients with significant unmet medical needs across a range of tumor types. The collaboration with Repare builds on Roche’s strategy of personalized healthcare and further strengthens our leadership in oncology.”

Under the terms of the agreement, Repare will receive a $125 million upfront payment, and is eligible to receive up to $1.2 billion in potential clinical, regulatory, commercial and sales milestones, including up to $55 million in potential near-term payments, and royalties on global net sales ranging from high-single-digits to high-teens. The collaboration also provides Repare with the ability to opt-in to a 50/50 U.S. co-development and profit share arrangement, including participation in U.S. co-promotion if U.S. regulatory approval is received. If Repare chooses to exercise its co-development and profit share option, it will continue to be eligible to receive certain clinical, regulatory, commercial and sales milestone payments, in addition to full ex-U.S. royalties.

The transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary closing conditions.

Company Conference Call:

The Company will host a conference call with accompanying slides for analysts and investors today at 5:00 p.m. Eastern Time to further discuss the collaboration. To access the call, please dial (877) 870-4263 (U.S.) or (855) 669-9657 (Canada) or (412) 317-0790 (international) at least 10 minutes prior to the start time and ask to be joined to the Repare Therapeutics call. A live video webcast will be available in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A webcast replay will also be archived for at least 30 days.

About Repare Therapeutics’ SNIPRx® Platform

Repare’s SNIPRx® platform is a genome-wide CRISPR-based screening approach that utilizes proprietary isogenic cell lines to identify novel and known synthetic lethal gene pairs and the corresponding patients who are most likely to benefit from the Company’s therapies based on the genetic profile of their tumors. Repare’s platform enables the development of precision therapeutics in patients whose tumors contain one or more genomic alterations identified by SNIPRx® screening, in order to selectively target those tumors in patients most likely to achieve clinical benefit from resulting product candidates.

About Repare Therapeutics, Inc.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes its lead product candidate camonsertib (also known as RP-3500), a potential leading ATR inhibitor currently in Phase 1/2 clinical development, its second clinical candidate, RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development, a Polθ inhibitor program, as well as several early-stage, pre-clinical programs. For more information, please visit reparerx.com.

SNIPRx® is a registered trademark of Repare Therapeutics Inc.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in Canada. All statements in this press release other than statements of historical facts are “forward-looking statements. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: Repare’s collaboration with Roche; the ability of the parties to complete the transaction in a timely manner or at all; the possibility that various closing conditions for the transaction may not be satisfied or waived, including the possibility that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the risk that Repare may not realize the potential benefits of this collaboration with Roche; the discovery, development and potential commercialization of potential product candidates using Repare’s SNIPRx® platform technology and under the strategic collaboration agreement, including the development of camonsertib; the ability of the parties to file applications for regulatory approval or receive regulatory approvals in a timely manner or at all; the therapeutic potential for camonsertib in oncology applications; and the potential of Repare to receive milestone payments and royalties under the strategic collaboration agreement. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including the impacts of the COVID-19 pandemic on the Company’s business, clinical trials and financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) and the Québec Autorité des Marchés Financiers (“AMF”) on March 1, 2022, and its other documents subsequently filed with or furnished to the SEC and AMF, including the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 filed with the SEC on May 5, 2022. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

Repare Contact:

Steve Forte

Chief Financial Officer

Repare Therapeutics Inc.

[email protected]

Investors:

Kimberly Minarovich

Argot Partners

[email protected]

Media:

David Rosen

Argot Partners

[email protected]

212-600-1902

KEYWORDS: Massachusetts United States North America Canada

INDUSTRY KEYWORDS: Oncology Health General Health Research Science Pharmaceutical Biotechnology

MEDIA:

Iteris Reports Record Full Year 2022 Revenue of $134 Million, Up 14% Year Over Year, and Record Full Year 2022 Bookings of $155 Million, Up 28% Year Over Year

Iteris Reports Record Full Year 2022 Revenue of $134 Million, Up 14% Year Over Year, and Record Full Year 2022 Bookings of $155 Million, Up 28% Year Over Year

Estimates Fiscal Full Year 2023 Total Revenue Range of $147 Million to $155 Million

SANTA ANA, Calif.–(BUSINESS WIRE)–Iteris, Inc. (NASDAQ: ITI), the world’s trusted technology ecosystem for smart mobility infrastructure management, today reported financial results for its fiscal fourth quarter and full year ended March 31, 2022. During the fiscal first quarter of 2021, the company completed the sale of its Agriculture and Weather Analytics segment to DTN, LLC. The results of the Agriculture and Weather Analytics segment are reported as discontinued operations for all periods presented in this release.

Fiscal Fourth Quarter 2022 Financial Highlights

  • Record revenue of $34.2 million, up 8% year over year

    • Service revenue increased 8% to $17.1 million due to continued adoption of Iteris’ ClearMobility® Platform
    • Product revenue increased 8% to $17.1 million despite $2.2 million in shipments slipping out of the quarter due to supply chain constraints
  • Record bookings of $41.9 million, up 27% year over year
  • Record ending backlog of $99.9 million, up 28% year over year
  • GAAP net loss from continuing operations of $3.0 million, or $(0.07), a $0.06 per share decrease from the prior year due to global supply chain disruptions and associated costs
  • Adjusted EBITDA of $(1.1) million, a $2.8 million decrease year over year due to global supply chain disruptions and associated costs

Fiscal Year 2022 Financial Highlights

  • Record revenue of $133.6 million, up 14% year over year

    • Service revenue increased 20% to $64.8 million due to continued adoption of Iteris’ ClearMobility Platform
    • Product revenue increased 9% to $68.7 million despite shipments slipping out of the period due to supply chain constraints
  • GAAP net loss from continuing operations of $6.9 million, or $(0.16) per share due to a second quarter noncash project write-off and increased costs related to global supply chain disruptions
  • Record bookings of $155.4 million, up 28% year over year
  • Adjusted EBITDA of $4.5 million, a $3.0 million decrease year over year due to global supply chain disruptions and associated increased costs

Fiscal Year 2023 Outlook

  • Total revenue of $147 million to $155 million, which represents organic growth of 13% year over year at the mid-point of the guidance range
  • Adjusted EBITDA of 5% to 6% of full fiscal year 2023 revenue, which assumes gradual improvements related to global supply chain disruptions

Management Commentary:

“We continued to experience strong customer demand for Iteris’ ClearMobility Platform, with fourth quarter and full year bookings growing 27% and 28%, respectively, year over year,” said Joe Bergera, president and CEO of Iteris. “In turn, our ending backlog, which we define as the total current value of firm fixed orders, grew 28% year over year to reach a record $99.9 million, positioning Iteris for accelerated organic revenue growth in fiscal 2023.

“Despite global supply chain disruptions, we are pleased to report record fourth quarter and fiscal year revenue rose 8% and 14%, respectively, year over year. We are committed to delivering both revenue and profit growth even in challenging economic cycles. Therefore, in our fiscal 2023 first quarter, we will consolidate our cloud solutions and advanced sensors teams to enhance our platform roadmap and create internal operating efficiencies. This will result in a pre-tax restructuring charge of $0.7 million in our fiscal 2023 first quarter and generate annualized cost savings of approximately $1.2 million. We are also executing a comprehensive multi-point plan, which includes redesigning certain circuit boards and increasing buffer stock for our Vantage sensors, to mitigate Iteris’ supply chain exposure. We expect these initiatives to progressively minimize the impact of supply chain disruption throughout the new fiscal year.

“Looking ahead, we believe Iteris is well positioned to capitalize on significant opportunities in our end-markets, including the oncoming tailwinds from the Infrastructure Investment and Jobs Act. As a result, our Board of Directors believes the Company’s stock is trading in a range that is disassociated from customer demand and our strategic opportunity. Therefore, they have authorized a new stock repurchase program whereby $10.0 million in common stock may be repurchased from time to time in the open market.”

GAAP Fiscal Fourth Quarter 2022 Financial Results

Revenue in the fourth quarter of fiscal 2022 increased 8% to $34.2 million, compared with $31.7 million in the same quarter a year ago. This revenue increase was primarily driven by sustained strong customer adoption of Iteris’ ClearMobility Platform.

Operating expenses in the fourth quarter increased 5% to $14.1 million, compared with $13.4 million in the same quarter a year ago. This increase was primarily due to expenses related to continued investment in research and development, and sales and marketing, while keeping general and administrative costs flat year over year.

Operating loss from continuing operations in the fourth quarter was approximately $3.0 million. The loss was primarily attributable to the continued supply chain constraints and increasing costs in raw materials. This compares with an operating loss from continuing operations of approximately $0.4 million in the same quarter a year ago. Net loss from continuing operations in the fourth quarter was approximately $3.0 million, or $(0.07) per share, compared with a net loss of approximately $0.4 million, or $(0.01) per share, in the same quarter a year ago.

GAAP Fiscal Year 2022 Financial Results

Revenue in fiscal 2022 increased 14% to $133.6 million, compared with $117.1 million in fiscal 2021. This revenue increase was driven primarily by the addition of revenues from TrafficCast and continued adoption of Iteris’ ClearMobility Platform.

Operating expenses in fiscal 2022 increased 17% to $54.1 million, compared with $46.4 million in fiscal 2021. This increase was primarily due to increased expenses related to research and development expenses, and sales and marketing.

Operating loss from continuing operations in fiscal 2022 was approximately $6.7 million, compared to operating income from continuing operations of approximately $0.4 million in the previous year period. This reduction was primarily attributable to the continued supply chain constraints, increasing raw materials costs, and a one-time, non-recurring charge of $3.4 million on a software development contract. Net loss from continuing operations in fiscal 2022 was approximately $6.9 million, or $(0.16) per share, compared with a net income of approximately $0.5 million, or $0.01 per share, in the previous year period.

Non-GAAP Fiscal Fourth Quarter and Fiscal Year 2022 Financial Results

In addition to results presented in accordance with generally accepted accounting principles in the United States (“GAAP”), the company has included the following non-GAAP financial measure: Adjusted income (loss) from continuing operations before interest, taxes, depreciation, amortization, stock-based compensation expense, restructuring charges, project loss reserves, acquisition costs, executive severance and transition costs, and fair value adjustment related to TrafficCast’s opening balance inventory (“Adjusted EBITDA”). A discussion of the company’s use of this non-GAAP financial measure is set forth below in the financial statements portion of this release under the heading “Non-GAAP Financial Measures and Reconciliation.”

Adjusted EBITDA in the fourth quarter of fiscal 2022 was approximately $(1.1) million, or (3.1)% of total revenues, compared with approximately $1.8 million, or 5.5% of total revenues, in the same quarter a year ago.

Adjusted EBITDA in fiscal 2022 was approximately $4.5 million, or 3.3% of total revenues, compared with approximately $7.5 million, or 6.4% of total revenues in fiscal 2021. These reductions were primarily attributable to continued supply chain constraints and increasing raw materials costs.

Earnings Conference Call

Iteris will conduct a conference call today to discuss its fiscal fourth quarter and full year 2022 results.

Date: Wednesday, June 1, 2022

Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)

Toll-free dial-in number: 877-317-6789

International dial-in number: +1 412-317-6789

If joining by phone, please call the conference telephone number 5-10 minutes prior to the start time and ask to join the Iteris earnings call. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact MKR Investor Relations at 1-213-277-5550.

To listen to the live webcast or view the press release, please visit the investor relations section of the Iteris website at www.iteris.com.

A telephone replay of the conference call will be available approximately two hours following the end of the call and will remain available for one week. To access the replay dial +1-877-344-7529 (US Toll Free), +1 855-669-9658 (Canada Toll Free), or +1 412-317-0088 (International) and enter replay passcode 9295290.

About Iteris, Inc.

Iteris is the world’s trusted technology ecosystem for smart mobility infrastructure management. Delivered through Iteris’ ClearMobility Platform, our cloud-enabled end-to-end solutions monitor, visualize and optimize mobility infrastructure around the world, and help bridge legacy technology silos to unlock the future of transportation. That’s why more than 10,000 public agencies and private-sector enterprises focused on mobility rely on Iteris every day. Visit www.iteris.com for more information, and join the conversation on Twitter, LinkedIn and Facebook.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This release may contain forward-looking statements, which speak only as of the date hereof and are based upon our current expectations and the information available to us at this time. Words such as “believes,” “anticipates,” “expects,” “intends,” “plans,” “feel(s),” “seeks,” “estimates,” “may,” “will,” “can,” and variations of these words or similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about the Company’s anticipated demand and growth opportunities, conversion of bookings to revenue, the impact and success of new solution offerings, the Company’s recent acquisition, our future performance, growth and profitability, operating results, and financial condition and prospects. Such statements are subject to certain risks, uncertainties, and assumptions that are difficult to predict and actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors.

Important factors that may cause such a difference include, but are not limited to, federal, state and local government budgetary issues, spending and scheduling changes, funding constraints and delays, including in light of the ongoing COVID-19 pandemic; the timing and amount of government funds allocated to overall transportation infrastructure projects and the transportation industry; our ability to replace large contracts once they have been completed; the effectiveness of efficiency, cost, and expense reduction efforts; our ability to achieve anticipated benefits from our sale of our Agriculture and Weather Analytics segment; our ability to successfully complete and integrate acquired assets and companies; our ability to specify, develop, complete, introduce, market and gain broad acceptance of our new and existing product and service offerings; risks related to our ability to recruit and/or retain key talent; the potential unforeseen impact of product and service offerings from competitors, increased competition in certain market segments, and such competitors’ patent coverage and claims; any softness in the markets that we address; adverse effects of the COVID-19 pandemic on our vendors and our employees; and the impact of general economic and political conditions and specific conditions in the markets we address, and the possible disruption in government spending and commercial activities, such as the COVID-19 pandemic, import/export tariffs, terrorist activities or armed conflicts in the United States and internationally. Further information on Iteris, Inc., including additional risk factors that may affect our forward-looking statements, as contained in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K, and our other SEC filings that are available through the SEC’s website (www.sec.gov).

ITERIS, INC.

UNAUDITED CONDENSED CONSOLIDATED

BALANCE SHEETS

(in thousands)

 

 

March 31,

 

2022

 

2021

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

23,689

 

$

25,205

Restricted cash

 

120

 

 

 

263

 

Short-term investments

 

 

 

 

3,100

 

Trade accounts receivable, net of allowance for doubtful accounts of $903 and $1,019 at March 31, 2022 and 2021, respectively

 

25,628

 

 

 

19,020

 

Unbilled accounts receivable

 

10,870

 

 

 

11,541

 

Inventories

 

7,980

 

 

 

5,066

 

Prepaid expenses and other current assets

 

4,076

 

 

 

5,445

 

Total current assets

 

72,363

 

 

 

69,640

 

Property and equipment, net

 

1,392

 

 

 

1,923

 

Right-of-use assets

 

11,382

 

 

 

11,353

 

Intangible assets, net

 

11,780

 

 

 

14,297

 

Goodwill

 

28,340

 

 

 

28,340

 

Other assets

 

1,120

 

 

 

1,238

 

Noncurrent assets of discontinued operations

 

6

 

 

 

78

 

Total assets

$

126,383

 

 

$

126,869

 

Liabilities and stockholders’ equity

 

 

 

Current liabilities:

 

 

 

Trade accounts payable

$

11,926

 

 

$

8,935

 

Accrued payroll and related expenses

 

11,409

 

 

 

11,734

 

Accrued liabilities

 

5,623

 

 

 

4,921

 

Deferred revenue

 

6,566

 

 

 

7,349

 

Current liabilities of discontinued operations

 

163

 

 

 

94

 

Total current liabilities

 

35,687

 

 

 

33,033

 

Long-term liabilities

 

13,661

 

 

 

14,596

 

Noncurrent liabilities of discontinued operations

 

172

 

 

 

261

 

Total liabilities

 

49,520

 

 

 

47,890

 

Stockholders’ equity

 

76,863

 

 

 

78,979

 

Total liabilities and stockholders’ equity

$

126,383

 

 

$

126,869

 

ITERIS, INC.

UNAUDITED CONDENSED CONSOLIDATED

STATEMENT OF OPERATIONS

(in thousands, except per share amounts)

 

Three Months Ended

March 31,

 

Twelve Months Ended

March 31,

2022

 

2021

 

2022

 

2021

 

 

 

 

 

 

 

 

Product revenues

$

17,097

 

 

$

15,894

 

 

$

68,729

 

 

$

62,933

 

Service revenues

 

17,139

 

 

 

15,818

 

 

 

64,843

 

 

 

54,205

 

Total revenues

 

34,236

 

 

 

31,712

 

 

 

133,572

 

 

 

117,138

 

Cost of product revenues

 

11,572

 

 

 

9,107

 

 

 

40,501

 

 

 

34,933

 

Cost of service revenues

 

11,588

 

 

 

9,625

 

 

 

45,678

 

 

 

35,349

 

Cost of revenues

 

23,160

 

 

 

18,732

 

 

 

86,179

 

 

 

70,282

 

Gross profit

 

11,076

 

 

 

12,980

 

 

 

47,393

 

 

 

46,856

 

Operating expenses:

 

 

 

 

 

 

 

General and administrative

 

6,698

 

 

 

6,690

 

 

 

25,131

 

 

 

24,207

 

Sales and Marketing

 

4,810

 

 

 

4,357

 

 

 

18,929

 

 

 

14,957

 

Research and development

 

1,909

 

 

 

1,647

 

 

 

7,354

 

 

 

5,130

 

Amortization of intangible assets

 

669

 

 

 

668

 

 

 

2,673

 

 

 

1,504

 

Restructuring charges

 

 

 

 

 

 

 

 

 

 

619

 

Total operating expenses

 

14,086

 

 

 

13,362

 

 

 

54,087

 

 

 

46,417

 

Operating income (loss)

 

(3,010

)

 

 

(382

)

 

 

(6,694

)

 

 

439

 

Non-operating income (expense):

 

 

 

 

 

 

 

Other income (expense)

 

(33

)

 

 

52

 

 

 

(18

)

 

 

54

 

Interest income (expense)

 

(22

)

 

 

5

 

 

 

(14

)

 

 

113

 

Income (loss) from continuing operations before income taxes

 

(3,065

)

 

 

(325

)

 

 

(6,726

)

 

 

606

 

Benefit (provision) for income taxes

 

27

 

 

 

(60

)

 

 

(174

)

 

 

(115

)

Net income (loss) from continuing operations

 

(3,038

)

 

 

(385

)

 

 

(6,900

)

 

 

491

 

Loss from discontinued operations before gain on sale, net of tax

 

(76

)

 

 

(8

)

 

 

(180

)

 

 

(1,654

)

Gain on sale of discontinued operations, net of tax

 

 

 

 

(22

)

 

 

 

 

 

11,297

 

Net income (loss) from discontinued operations, net of tax

 

(76

)

 

 

(30

)

 

 

(180

)

 

 

9,643

 

Net income (loss)

$

(3,114

)

 

$

(415

)

 

$

(7,080

)

 

$

10,134

 

 

 

 

 

 

 

 

Income (loss) per share – basic:

 

 

 

 

 

 

 

Income (loss) per share from continuing operations

$

(0.07

)

 

$

(0.01

)

 

$

(0.16

)

 

$

0.01

 

Income per share from discontinued operations

$

0.00

 

 

$

0.00

 

 

$

0.00

 

 

$

0.23

 

Net income (loss) per share

$

(0.07

)

 

$

(0.01

)

 

$

(0.16

)

 

$

0.24

 

 

 

 

 

 

 

 

Income (loss) per share – diluted:

 

 

 

 

 

 

 

Income (loss) per share from continuing operations

$

(0.07

)

 

$

(0.01

)

 

$

(0.16

)

 

$

0.01

 

Income per share from discontinued operations

$

0.00

 

 

$

0.00

 

 

$

0.00

 

 

$

0.23

 

Net income (loss) per share

$

(0.07

)

 

$

(0.01

)

 

$

(0.16

)

 

$

0.24

 

 

 

 

 

 

 

 

Shares used in basic per share calculations

 

42,398

 

 

 

41,637

 

 

 

42,222

 

 

 

41,176

 

Shares used in diluted per share calculations

 

42,398

 

 

 

41,637

 

 

 

42,222

 

 

 

41,599

 

ITERIS, INC.

Non-GAAP Financial Measures and Reconciliation

In addition to results presented in accordance with GAAP, the company has included the following non-GAAP financial measure in this release: Adjusted income (loss) from continuing operations before interest, taxes, depreciation, amortization, stock-based compensation expense, restructuring charges, project loss reserves, acquisition costs, executive severance and transition costs, and fair value adjustment related to TrafficCast’s opening balance inventory (“Adjusted EBITDA”).

When viewed with our financial results prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”) and accompanying reconciliations, we believe Adjusted EBITDA provides additional useful information to clarify and enhance the understanding of the factors and trends affecting our past performance and future prospects. We define these measures, explain how they are calculated and provide reconciliations of these measures to the most comparable GAAP measure in the table below. Adjusted EBITDA and the related financial ratios, as presented in this Annual Report on Form 10-K (“Form 10-K”), are supplemental measures of our performance that are not required by or presented in accordance with GAAP. They are not a measurement of our financial performance under GAAP and should not be considered as alternatives to net income or any other performance measures derived in accordance with GAAP, or as an alternative to net cash provided by operating activities as measures of our liquidity. The presentation of these measures should not be interpreted to mean that our future results will be unaffected by unusual or nonrecurring items.

We use Adjusted EBITDA non-GAAP operating performance measures internally as complementary financial measures to evaluate the performance and trends of our businesses. We present Adjusted EBITDA and the related financial ratios, as applicable, because we believe that measures such as these provide useful information with respect to our ability to meet our operating commitments.

Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations include:

  • They do not reflect our cash expenditures, future requirements for capital expenditures or contractual commitments;
  • They do not reflect changes in, or cash requirements for, our working capital needs;
  • Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements;
  • They are not adjusted for all non-cash income or expense items that are reflected in our statements of cash flows;
  • They do not reflect the impact on earnings of charges resulting from matters unrelated to our ongoing operations; and
  • Other companies in our industry may calculate Adjusted EBITDA differently than we do, whereby limiting its usefulness as comparative measures.

Because of these limitations, Adjusted EBITDA and the related financial ratios should not be considered as measures of discretionary cash available to us to invest in the growth of our business or as a measure of cash that will be available to us to meet our obligations. You should compensate for these limitations by relying primarily on our GAAP results and using Adjusted EBITDA only as supplemental information. See our audited consolidated financial statements contained in our Form 10-K. However, in spite of the above limitations, we believe that Adjusted EBITDA is useful to an investor in evaluating our results of operations because these measures:

  • Are widely used by investors to measure a company’s operating performance without regard to items excluded from the calculation of such terms, which can vary substantially from company to company depending upon accounting methods and book value of assets, capital structure and the method by which assets were acquired, among other factors;
  • Help investors to evaluate and compare the results of our operations from period to period by removing the effect of our capital structure from our operating performance; and
  • Are used by our management team for various other purposes in presentations to our Board of Directors as a basis for strategic planning and forecasting.

The following financial items have been added back to or subtracted from our net income (loss) when calculating Adjusted EBITDA:

  • Interest expense. Iteris excludes interest expense because it does not believe this item is reflective of ongoing business and operating results. This amount may be useful to investors for determining current cash flow.
  • Income tax. This amount may be useful to investors because it represents the taxes which may be payable for the period and the change in deferred taxes during the period, and may reduce cash flow available for use in our business.
  • Depreciation expense. Iteris excludes depreciation expense primarily because it is a non-cash expense. These amounts may be useful to investors because it generally represents the wear and tear on our property and equipment used in our operations.
  • Amortization. Iteris incurs amortization of intangible assets in connection with acquisitions. Iteris also incurs amortization related to capitalized software development costs. Iteris excludes these items because it does not believe that these expenses are reflective of ongoing operating results in the period incurred. These amounts may be useful to investors because it represents the estimated attrition of our acquired customer base and the diminishing value of product rights.
  • Stock-based compensation. These expenses consist primarily of expenses from employee and director equity based compensation plans Iteris excludes stock-based compensation primarily because they are non-cash expenses and Iteris believes that it is useful to investors to understand the impact of stock-based compensation to its results of operations and current cash flow.
  • Restructuring charges. These expenses consist primarily of employee separation expenses, facility termination costs, and other expenses associated with Company restructuring activities. Iteris excludes these expenses as it does not believe that these expenses are reflective of ongoing operating results in the period incurred. These amounts may be useful to our investors in evaluating our core operating performance.
  • Project loss reserves. These expenses consist primarily of expenses incurred to complete a software development contract that will not be recoverable and are largely related to previously incurred and capitalized costs for non-recurring engineering activity. Iteris excludes these expenses as it does not believe that these expenses are reflective of ongoing operating results in the period incurred. These amounts may be useful to our investors in evaluating our core operating performance.
  • Acquisition costs. In connection with its business combinations, Iteris incurs professional service fees, changes to the fair value of contingent consideration, and other direct expenses. Iteris excludes such items as they are related to acquisitions and have no direct correlation to the operation of Iteris’ business. These amounts may be useful to our investors in evaluating our core operating performance.
  • Executive severance and transition costs. Iteris excludes executive severance and transition costs because it does not believe that these expenses are reflective of ongoing operating results in the period incurred. These amounts may be useful to our investors in evaluating our core operating performance.
  • Fair value adjustment related to acquired opening balance inventories. Iteris excludes fair value adjustment related to the opening inventory balance acquired as part of its business combination because it does not believe that these costs are reflective of operating results in the period incurred. These amounts may be useful to our investors in evaluating our core operating performance.

Reconciliations of net income (loss) from continuing operations to Adjusted EBITDA and the presentation of Adjusted EBITDA as a percentage of net revenues were as follows:

 

Three Months Ended

December 31,

 

Twelve Months Ended

March 31,

 

2022

 

2021

 

2022

 

2021

 

(In Thousands)

 

(In Thousands)

Net income (loss) from continuing operations

$

(3,038

)

 

$

(385

)

 

$

(6,900

)

 

$

491

 

 

 

 

 

 

 

 

 

Income tax expense

 

(27

)

 

 

60

 

 

 

174

 

 

 

115

 

Depreciation expense

 

191

 

 

 

183

 

 

 

820

 

 

 

734

 

Amortization expense

 

812

 

 

 

800

 

 

 

3,240

 

 

 

2,036

 

Stock-based compensation

 

1,005

 

 

 

831

 

 

 

3,401

 

 

 

2,902

 

Other adjustments:

 

 

 

 

 

 

 

Restructuring charges

 

 

 

 

 

 

 

 

 

 

619

 

Project loss reserve

 

 

 

 

 

 

 

3,394

 

 

 

 

Acquisition costs

 

 

 

 

132

 

 

 

 

 

 

417

 

Executive severance and transition costs

 

 

 

 

 

 

 

340

 

 

 

 

Fair value adjustment – opening balance inventories

 

 

 

 

136

 

 

 

 

 

 

136

 

Total adjustments

 

1,981

 

 

 

2,142

 

 

 

11,369

 

 

 

6,959

 

Adjusted EBITDA

$

(1,057

)

 

$

1,757

 

 

$

4,469

 

 

$

7,450

 

Percentage of total revenues

 

(3.1

)%

 

 

5.5

%

 

 

3.3

%

 

 

6.4

%

 

Iteris Contact

Douglas Groves ​​​​​​​

Senior Vice President and Chief Financial Officer

Tel: (949) 270-9643

Email: [email protected]

Investor Relations

MKR Investor Relations, Inc.

Todd Kehrli

Tel: (213) 277-5550

Email: [email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Other Transport Public Transport Technology Automotive General Automotive Transport Software Hardware Fleet Management

MEDIA:

Logo
Logo

SITE Centers Declares Second Quarter 2022 Class A Preferred Share Dividend

SITE Centers Declares Second Quarter 2022 Class A Preferred Share Dividend

BEACHWOOD, Ohio–(BUSINESS WIRE)–
SITE Centers Corp. (NYSE: SITC), an owner of open-air shopping centers in suburban, high household income communities, today declared its second quarter 2022 Preferred Class A stock dividend of $0.39844 per depositary share.

Each Class A depositary share is equal to one-twentieth of a share of SITE Centers’ 6.375% Class A Cumulative Redeemable Preferred Stock. The declared Preferred Class A dividend covers the period beginning April 15, 2022 and ending July 14, 2022. The declared Preferred Class A Dividend is payable in cash on July 15, 2022 to shareholders of record at the close of business on June 29, 2022.

About SITE Centers Corp.

SITE Centers is an owner and manager of open-air shopping centers located in suburban, high household income communities. The Company is a self-administered and self-managed REIT operating as a fully integrated real estate company, and is publicly traded on the New York Stock Exchange under the ticker symbol SITC. Additional information about the Company is available at www.sitecenters.com. To be included in the Company’s e-mail distributions for press releases and other investor news, please click here.

Conor Fennerty, EVP and

Chief Financial Officer

216-755-5500

KEYWORDS: Ohio United States North America

INDUSTRY KEYWORDS: Retail Other Retail Department Stores Commercial Building & Real Estate Construction & Property REIT

MEDIA:

Logo
Logo

Savara to Present at Jefferies Healthcare Conference

Savara to Present at Jefferies Healthcare Conference

AUSTIN, Texas–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Jefferies Healthcare Conference on June 8, 2022 at 1:00 pm ET in New York City. A live webcast of the presentation will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

Savara Inc. IR & PR

Anne Erickson

Senior Vice President, Chief of Staff

[email protected]

(512) 851-1366

KEYWORDS: United States North America Texas New York

INDUSTRY KEYWORDS: Health Other Science Clinical Trials Pharmaceutical Science Biotechnology

MEDIA:

Logo
Logo

HireRight Announces Participation in Upcoming Conferences

HireRight Announces Participation in Upcoming Conferences

NASHVILLE, Tenn.–(BUSINESS WIRE)–
HireRight (NYSE: HRT) today announced that senior members of its management team will present at the following upcoming investor conferences:

Baird 2022 Global Consumer, Technology and Services Conference on June 6, 2022. The presentation will take place at 10:15 A.M ET.

Stifel 2022 Cross Sector Insight Conference on June 7, 2022. The presentation will take place at 8:35 A.M. ET and be viewable here.

William Blair 42nd Annual Growth Stock Conference on June 8, 2022. The presentation will take place at 10:00 A.M ET and be viewable here.

Webcasts of management presentations will also be viewable on the Company’s investor relations website at https://ir.hireright.com/.

About HireRight

HireRight is a leading global provider of technology-driven workforce risk management and compliance solutions. We provide comprehensive background screening, verification, identification, monitoring, and drug and health screening services for more than 40,000 customers across the globe. HireRight offers services via a unified global software and data platform that tightly integrates into its customers’ human capital management systems enabling highly effective and efficient workflows for workforce hiring, onboarding, and monitoring. In 2021, HireRight screened over 29 million job applicants, employees and contractors for its customers and processed over 110 million screens. For more information, visit www.HireRight.com.

Investors:

[email protected]

Media:

[email protected]

KEYWORDS: United States North America Tennessee

INDUSTRY KEYWORDS: Technology Human Resources Other Technology Professional Services Software Health General Health Data Management Other Professional Services

MEDIA:

Logo
Logo

Teradata Elects Todd McElhatton to Board of Directors

Teradata Elects Todd McElhatton to Board of Directors

Brings Proven Business Leadership of Cloud Transformation Activities and Financial Expertise

SAN DIEGO–(BUSINESS WIRE)–Teradata (NYSE: TDC) today announced the election of Todd McElhatton to its Board of Directors, effective June 1, 2022. With his election, Teradata expanded the size of the Board from 9 to 10 directors, nine of whom are independent.

McElhatton brings more than 25 years of corporate finance leadership experience, with specific emphasis on the shift from enterprise software to the cloud. He currently serves as Chief Financial Officer of Zuora, an NYSE-listed cloud-based subscription management software company, a position he has held since June 2020. He previously held various roles at SAP, including SVP and CFO of the Cloud Business Group, where he led the execution of the financial vision for its cloud business strategy across multiple lines of business globally, and SVP and CFO of SAP North America, where he provided oversight to SAP’s financial activities in the United States and Canada. Prior to that, McElhatton served as CFO of VMware’s Hybrid Cloud Business, Vice President of Oracle’s Cloud Services, and CFO of Hewlett Packard’s Managed Services Business.

“Todd’s expertise at the intersection of finance and cloud transformation directly aligns with Teradata’s strategic plan and will be a tremendous asset as we continue to execute our own transformation and drive sustainable profitable growth,” said Mike Gianoni, Chairman of the Board. “Our ongoing efforts to enhance the cloud expertise of our Board is a testament to our commitment to supporting Teradata’s growth objectives, and we are delighted to welcome Todd to the Board.”

McElhatton said, “Teradata has seen tremendous success in its cloud transformation with an exciting roadmap ahead. Strategic capital investment and discipline are core to Teradata’s execution, and I look forward to working with the Board to help build on Teradata’s progress and momentum.”

McElhatton was selected following a comprehensive search conducted by the Board and he has been elected as a Class III director. He will serve as a member of Teradata’s Audit Committee and has been designated as an Audit Committee Financial Expert. McElhatton holds a B.A. in Business Administration from Southern Methodist University and an M.B.A. from the University of Tennessee.

About Teradata

Teradata is the connected multi-cloud data platform for enterprise analytics company. Our enterprise analytics solve business challenges from start to scale. Only Teradata gives you the flexibility to handle the massive and mixed data workloads of the future, today. Learn how at Teradata.com.

The Teradata logo is a trademark, and Teradata is a registered trademark of Teradata Corporation and/or its affiliates in the U.S. and worldwide.

Jennifer Donahue

858-485-3029 office

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Networks Internet Data Management Technology Software

MEDIA:

Floor & Decor Launches the Grand Opening of its Wilmington, North Carolina Store on June 6, 2022

Floor & Decor Launches the Grand Opening of its Wilmington, North Carolina Store on June 6, 2022

Grand Opening Celebration and Pro Event

ATLANTA–(BUSINESS WIRE)–Floor & Decor (NYSE: FND), a leading specialty retailer of hard-surface flooring, will expand its nationwide footprint when it opens the doors to its newest location in Wilmington, North Carolina on June 6, 2022. The Floor & Decor warehouse store and design center will be led by Milissia Sparkman, the new store’s Chief Executive Merchant.

“Floor & Decor is excited to open a store in Wilmington,” said Sparkman. “We are eager to introduce both Professional customers and Homeowners to our one-stop solution for their flooring needs with an extensive selection of in-stock, trend-right flooring options. We offer great service and quality flooring at unbeatable prices.”

$5,000 Floor Makeover Sweepstakes

The Wilmington Floor & Decor store will be giving away a $5,000 Floor Makeover as part of its grand opening festivities. Starting on May 30, customers will have the chance to register to win a $5,000 gift card from Floor & Decor. Interested parties can register online at www.floormakeoverwilmington.com. Registration ends on July 3, 2022.

Calling All Pros

Floor & Decor welcomes its valued builders, contractors, architects, designers, remodelers, flooring installers and realtors to visit the new location in the Cleveland market. Pros are invited to attend a special Pro VIP Grand Opening event on June 30. They can visit http://www.flooranddecor.com/wilmingtonpro to RSVP and register to win a Chevrolet Silverado truck and other great prizes like an iPad, Nintendo Switch, Otterbox, GoPro Hero and so much more! During the event, visitors will get to meet the PRO Services Team, interact with supplier representatives, and learn about Floor & Decor’s products and services.

“It is essential to us to build relationships with our local professionals. Their success is our success,” said Sparkman. “The store tours and giveaways give us a chance to support our community and tell them about our PRO Premier Rewards and all the benefits it can bring to their business.”

Store Address: 816 S College Rd., Wilmington NC 28403

About Floor & Decor: Founded in 2000, Atlanta-based Floor & Decor is a leading high-growth specialty retailer of hard-surface flooring, operating 166 warehouse-format stores and five design studios across 34 states as of March 31, 2022. The stores offer homeowners and professionals the industry’s broadest in-stock selection of tile, natural wood, natural stone, laminate, and luxury vinyl plank, under one roof. In addition, Floor & Decor stocks the necessary tools, decorative materials, wall tile, and related accessories for hard-surface flooring projects. Stores carry over 1 million square feet of in-stock flooring and offer free design services, as well as a dedicated pro sales team. The company directly sources products from manufacturers around the globe, which enables it to bring the world’s best and most innovative flooring trends to its customers, at everyday low prices. Floor & Decor has locations nationwide, but each store is bolstered by a local focus that creates a store experience and mix of products that meet the needs of each market served.

Additional company information can be found at www.flooranddecor.com and on Facebook (www.facebook.com/flooranddecor).

CONTACT:

Deanna Pierce

Floor & Decor

[email protected]

404-471-1634

KEYWORDS: North Carolina Georgia United States North America

INDUSTRY KEYWORDS: Interior Design Other Retail Other Construction & Property Retail Construction & Property

MEDIA: